This population-based study shows rising medical costs in primary biliary cholangitis patients, suggesting tailored treatments reduce them.
The overall (total, inpatient and outpatient) and mean outpatient costs for PBC patients increased over time. Special attention and tailored treatments should be given to PBC subgroups, including males, elderly people, southern Taiwan residents, those with hepatic events, and those with diabetes, as this approach might effectively reduce medical costs. A new drug that is effective and costs ≤ NTD 20,417/year would benefit PBC patients in Taiwan.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: